Businesses Turning to GenAI for Purchase Decisions

Why It Matters

The shift to AI‑augmented buying reshapes vendor engagement, demanding proof of ROI and coordinated outreach across larger, risk‑averse buying networks.

Key Takeaways

• 36% of B2B buyers rely on genAI for purchases
• Buying groups average 13 internal, nine external stakeholders
• Procurement leads 53% of buying cycles
• 94% of large groups report clearer budget approval
• Trials used by 60%+ buyers; 78% for >$10M deals

Pulse Analysis

The rise of generative AI in B2B procurement marks a fundamental change in how organizations source technology. By surfacing niche vendors and condensing initial research, genAI has become the top touchpoint for 36% of buyers, eclipsing traditional channels such as vendor websites and trade shows. Yet the technology’s speed does not translate into faster deal closure; buyers still lean on human expertise and trusted networks to validate recommendations, especially amid economic uncertainty and geopolitical risk.

Concurrently, buying groups are swelling in size and complexity. Forrester data shows an average of 13 internal stakeholders and nine external influencers per purchase, with procurement professionals steering more than half of all cycles. This collaborative approach yields measurable benefits—94% of groups with six or more members report clearer budget approval, broader perspective, and reduced risk. The heightened scrutiny drives a surge in trial adoption; over 60% of buyers now test solutions before committing, and that figure climbs to 78% for contracts exceeding $10 million, reflecting a demand for tangible proof of performance.

Vendors must adapt by aligning their go‑to‑market tactics with this AI‑human hybrid buying model. Differentiated value propositions that quantify ROI, operational efficiency, and resilience are essential to earn trust. Moreover, sellers should actively engage the extended buying network—leveraging industry experts, case studies, and peer references—to complement AI insights. Designing trials that mirror real‑world use cases transforms them from mere access points into strategic conversion tools, helping buyers mitigate uncertainty and accelerate consensus across the expanded stakeholder landscape.